P0539 Prevalence of QuantiFERON Positivity in Patients with Inflammatory Bowel Disease Eligible for Biological Therapy: Clinical and Demographic Analysis
Authors: Guinea Lagunes A , Philippe Ponce M , Contreras Aviles E , Almeida del Prado G , López Perez R , Esquivel Steffanoni M , Jiménez Bobadilla B , De Leon Rendon J L 
Published: January 2025

Background

Inflammatory Bowel Disease (IBD), when treated with biological therapies, increases the risk of infections such as tuberculosis (TB). QuantiFERON-TB Gold (QFT) is a diagnostic tool used to detect latent tuberculosis (LTBI) in immunosuppressed patients. Evaluating the prevalence of QFT positivity in IBD patients who are eligible for biological therapies is of utmost importance. Understanding the prevalence of latent TB in this population will help in implementing better preventive and therapeutic strategies.

Methods

A cross-sectional and relational study was conducted at the Inflammatory Bowel Disease Clinic of the General Hospital of Mexico “Dr. Eduardo Liceaga,” involving 67 patients diagnosed with IBD and candidates for biological therapy. Clinical and demographic characteristics of each patient were collected, including QuantiFERON-TB Gold (QFTB) results. All patients underwent bacilloscopy, culture, and CRP testing for tuberculosis. For statistical analysis, measures of central tendency (mean and standard deviation) were used for continuous variables, while frequencies and percentages were used for categorical variables. Comparisons between groups were performed using Student’s t-tests for continuous variables and chi-square tests for categorical variables. The analysis was conducted using SPSS statistical software, version 29.

Results

Of the 67 patients with IBD included in the study, 26.86% tested positive for QFTB. Significant differences were observed in the age at diagnosis (45 ± 16.59 years in positives vs. 35.16 ± 14.64 years in negatives, p &lt; 0.05) and the duration of the disease (12 ± 0.73 months in positives vs. 36 ± 0.64 months in negatives, p &lt; 0.05). Additionally, a higher prevalence of arthralgia was noted in the positive group (61.1% vs. 38.8%, p &lt; 0.05). No significant differences were found in gender, age, type of diagnosis (UC vs. CD), or clinical CRP course of the disease between the groups. All patients underwent bacilloscopy, culture, and testing for tuberculosis, all of which were negative. Patients who began advanced therapies received prophylactic antituberculous treatment. Table 1 shows the clinical and demographic characteristics of the patients included in the study.

Conclusion

This study found a 26.86% prevalence of QuantiFERON positivity in patients with IBD. The results provide crucial data on the demographic and clinical characteristics of this population, highlighting the importance of latent tuberculosis detection and the implementation of antituberculous prophylaxis before initiating biological therapies. These measures are essential to prevent TB reactivation and improve the clinical management of patients with IBD.

References

Vajravelu RK, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, Scott FI. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflamm Bowel Dis. 2017 Dec 19;24(1):217-226. doi: 10.1093/ibd/izx019. PMID: 29272482; PMCID: PMC7007987.

Lai HC, Chang CH, Cheng KS, Chen TW, Tsai YY, Chou JW. QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan. Gastroenterol Res Pract. 2019 Nov 3;2019:7132875. doi: 10.1155/2019/7132875. PMID: 31781198; PMCID: PMC6875270.

Calzada-Hernández J, Anton-López J, Bou-Torrent R, Iglesias-Jiménez E, Ricart-Campos S, Martín de Carpi J; Carmen García de Vicuña Muñoz de la Nava; Torrente-Segarra V, Sánchez-Manubens J, Giménez-Roca C, Rozas-Quesada L, Juncosa-Morros MT, Fortuny C, Noguera-Julian A. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study. Pediatr Rheumatol Online J. 2015 Dec 3;13:54. doi: 10.1186/s12969-015-0054-4. PMID: 26635208; PMCID: PMC4669612.

Calzada-Hernández J, Anton J, Martín de Carpi J, López-Montesinos B, Calvo I, Donat E, Núñez E, Blasco Alonso J, Mellado MJ, Baquero-Artigao F, Leis R, Vegas-Álvarez AM, Medrano San Ildefonso M, Pinedo-Gago MDC, Eizaguirre FJ, Tagarro A, Camacho-Lovillo M, Pérez-Gorricho B, Gavilán-Martín C, Guillén S, Sevilla-Pérez B, Peña-Quintana L, Mesa-Del-Castillo P, Fortuny C, Tebruegge M, Noguera-Julian A. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain. Eur J Pediatr. 2023 Jan;182(1):307-317. doi: 10.1007/s00431-022-04640-3. Epub 2022 Nov 5. PMID: 36335186; PMCID: PMC9829583.